Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Summary

The goal of this protocol is to determine autophagic levels in pancreatic cancer and pancreatic acinar cells through LC3 immunofluorescence and LC3 dot quantification.

Abstract

Autophagy is a specialized catabolic process that selectively degrades cytoplasmic components, including proteins and damaged organelles. Autophagy allows cells to physiologically respond to stress stimuli and, thus, maintain cellular homeostasis. Cancer cells might modulate their autophagy levels to adapt to adverse conditions such as hypoxia, nutrient deficiency, or damage caused by chemotherapy. Ductal pancreatic adenocarcinoma is one of the deadliest types of cancer. Pancreatic cancer cells have high autophagy activity due to the transcriptional upregulation and post-translational activation of autophagy proteins.

Here, the PANC-1 cell line was used as a model of pancreatic human cancer cells, and the AR42J pancreatic acinar cell line was used as a physiological model of highly differentiated mammalian cells. This study used the immunofluorescence of microtubule-associated protein light chain 3 (LC3) as an indicator of the status of autophagy activation. LC3 is an autophagy protein that, in basal conditions, shows a diffuse pattern of distribution in the cytoplasm (known as LC3-I in this condition). Autophagy induction triggers the conjugation of LC3 to phosphatidylethanolamine on the surface of newly formed autophagosomes to form LC3-II, a membrane-bound protein that aids in the formation and expansion of autophagosomes. To quantify the number of labeled autophagic structures, the open-source software FIJI was utilized with the aid of the "3D Objects Counter" tool.

The measure of the autophagic levels both in physiological conditions and in cancer cells allows us to study the modulation of autophagy under diverse conditions such as hypoxia, chemotherapy treatment, or the knockdown of certain proteins.

Introduction

Macroautophagy (commonly referred to as autophagy) is a specialized catabolic process that selectively degrades cytoplasmic components, including proteins and damaged organelles^1,2. Autophagy allows cells to physiologically respond to stress stimuli and, thus, maintain cellular homeostasis³. During autophagy, a double membrane vesicle is formed: the autophagosome. The autophagosome contains the cargo molecules and drives them to the lysosome for degradation^1,4.

Autophagosomes are decorated by the autophagic protein microtubule-associated protein light chain 3 (LC3)⁵. When autophagy is not induced, LC3 is diffused in the cytoplasm and nucleus in the LC3-I conformation. On the other hand, when autophagy is induced, LC3 is conjugated with a phosphatidylethanolamine in the membrane of the autophagic structures⁶. This new LC3 conformation is known as LC3-II¹. The LC3 conformation shift causes changes in its cellular localization and its dodecyl sodium sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) migration, which can be detected by techniques such as immunofluorescence and western blot^5,7. In this way, LC3 conjugation is a key event in the autophagic process that can be used to measure autophagic activity.

The pancreatic acinar cell is a highly differentiated cell that, under healthy conditions, has a low rate of autophagy. However, in different physiological conditions or under pharmacological stimulation, they can activate autophagy. Therefore, the determination of autophagic levels in this cell line is useful for studying the potential direct or indirect effects of different pharmacological or biological agents on autophagy^8,9.

Ductal pancreatic adenocarcinoma is one of the deadliest types of cancer, given its late diagnosis and its high chemotherapy resistance¹⁰. Pancreatic cancer cells have high autophagy activity due to the transcriptional upregulation and post-translational activation of autophagy-related proteins¹¹. Pancreatic cancer cells may adjust their autophagy levels in response to unfavorable conditions like hypoxia, nutrient deprivation, or chemotherapy-induced damage¹¹. Hence, analyzing the autophagy levels in pancreatic cancer cells can help understand how they adapt to varying environments and evaluate the effectiveness of autophagy-modulating treatments.

This study shows a method to perform LC3 immunofluorescence in two distinct pancreatic cellular models. The first model, PANC-1 cells, served as a model for pancreatic ductal adenocarcinoma. These cells were treated with gemcitabine, a chemotherapy agent that has previously been shown to induce autophagy, specifically in pancreatic cancer cells carrying the oncogenic Kirsten rat sarcoma virus gene (KRAS)^12,13. The second model, AR42J cells, served as a more physiological model of exocrine pancreatic cells. These cells were differentiated with dexamethasone to become more similar to acinar pancreatic cells¹⁴. In these cells, autophagy was pharmacologically induced through the use of PP242, which is a potent mTOR inhibitor¹⁵. In this study, we demonstrate the applicability of the protocol described with two different pancreatic models and its ability to discriminate between states of low and high autophagy.

Protocol

1. Cell preparation

1. Soak 12 mm round coverslips in absolute ethanol, and place them vertically in the wells of a 24-well plate.
2. Remove the cover, and expose the multi-well plate to ultraviolet radiation for 15 min.
3. Position the coverslips horizontally, and wash them with Dulbecco's Modified Eagle Medium (DMEM).
4. Seed a low passage number of pancreatic cells. The amount should be adjusted to obtain 50%-75% confluency on the day of fixation¹⁶.
   NOTE: It is recommended to seed 2.5 × 10⁴ PANC-1 or 4 × 10⁴ AR42J cells per well to fixate the cells after 3 days.
5. Culture the cells in DMEM containing 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin in an incubator at 37 °C under a humidified atmosphere with 5% carbon dioxide (CO₂).
   ​NOTE: For PANC-1 cells, it is recommended to incubate the cells for 2 days between cell seeding and the following steps. After this time, the cells can be transfected, treated, or fixated. This protocol exemplifies the treatment with gemcitabine in non-transfected PANC-1 cells and the differentiation and PP242 treatment for non-transfected AR42J cells.

2. Treating the cells

1. Gemcitabine treatment for PANC-1 cells
   1. Prepare a solution of 1 µg/µL gemcitabine in DMEM 2 days after seeding. Treat each well with 2.6 µL of the 1 µg/µL gemcitabine solution to achieve a final dilution of 20 µM.
   2. Incubate the cells for 24 h in the incubator.
2. AR42J differentiation and PP242 treatment
   1. Prepare a solution of 4 µg/mL dexamethasone in DMEM.
   2. Treat each well with 4.9 µL of 4 µg/mL dexamethasone solution to obtain a final dilution of 100 nM.
   3. Incubate the cells for 48 h in the incubator.
   4. Remove the medium, and treat each well with 0.5 µL of 1 mM PP242 to obtain a final dilution of 1 µM.
   5. Incubate the cells for 2 h in the incubator.

3. Fixing and permeabilizing the cells

1. Prepare a 24-well plate with cold methanol and a 6-well plate with cold phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 8 mM Na₂HPO₄, 2 mM KH₂PO₄). Maintain them on ice.
2. Take each coverslip with tweezers, wash it twice in PBS, and incubate for 6 min in methanol.

4. Blocking the cells

1. Wash each coverslip twice in PBS, and incubate for 1 h in 10% fetal bovine serum in PBS (blocking solution).
   ​NOTE: In this step, the protocol might be paused. The coverslips can be stored overnight in the fridge in the blocking solution, and the protocol can be continued the following day.

5. Incubating the coverslips with the primary antibody

1. Prepare a 1:1,000 solution of anti-LC3 in the blocking solution, and maintain it on ice.
2. Place a piece of laboratory sealing film over the multi-well lid.
3. Place one drop (25 µL) per coverslip of anti-LC3 solution over the sealing film.
4. Take each coverslip with tweezers, and place it over the primary antibody drop, taking care that the cell side is in contact with the solution.
5. Prepare a humid chamber by placing a humid piece of paper into a flat-bottom plastic box.
6. Place the multi-well plate into the humidity chamber, cover it with foil, and incubate overnight in the fridge.

6. Incubating the coverslips with the secondary antibody

1. Remove the multi-well plate from the humidity chamber, and place the coverslips back in the multi-well plate.
2. Perform three washes with PBS.
3. Prepare a solution of fluorescently labeled anti-rabbit with a dilution of 1:800 in the blocking solution, and maintain it on ice protected from light.
4. Place a sealing film piece over the multi-well lid.
5. Place a drop (25 µL) per coverslip of anti-rabbit solution over the sealing film.
6. Take each coverslip with tweezers, and place it over the primary antibody drop, taking care that the cell side is in contact with the solution.
7. Incubate the multi-well plate in the humidity chamber for 2 h at room temperature (RT) protected from light.

7. Staining the cells with 4′ ,6-diamidino-2-phenylindole (DAPI)

1. Remove the multi-well plate from the humidity chamber, and place the coverslips back in the multi-well plate.
2. Perform three washes with PBS.
3. Prepare a 300 nM solution of DAPI in PBS (protected from light).
4. Incubate each coverslip with the DAPI solution for 10 min.
5. Perform three washes with PBS. Maintain the multi-well plate protected from light.

8. Montage

1. Prepare two beakers with water and a piece of paper.
2. Place one drop (10 µL) per coverslip of a polyvinyl alcohol-Bis(trimethylaluminum)-1,4-diazabicyclo[2.2.2]octane adduct (PVA-DABCO) solution on a slide.
   NOTE: PVA-DABCO is prepared by combining 0.25 M DABCO, 10% W/V PVA, 20% glycerol, and 50% Tris HCl (1.5 M, pH 8.8) in ultrapure water.
3. Take each coverslip with tweezers, wash it in each water beaker, dry it off in the paper, and place it over the PVA-DABCO drop (with the cells in contact with the solution).
4. Let it dry overnight, protected from light.

9. Confocal microscopy viewing and image capture

1. Visualize the coverslips in an inverted confocal microscope using an objective of around 63x¹⁷.
2. Capture representative images of the labeled cells.

10. Quantifying the LC3 dots

1. Drag and drop each image file containing the captured channels, such as ".czi", into the ImageJ (FIJI) screen to open. Click on Ok in the dialog box, and close the Console window.
2. From the Image tab, select Color > Split Channels.
3. Close the images corresponding to the channels other than the LC3 image.
4. From the Image tab, select Adjust > Color Balance
5. Move the Maximum slider to the left until the image is saturated to visualize the cell contours.
6. Draw the cell outline with the Freehand Selection tool.
7. Click on the Reset button to reset the color adjustment.
8. From the Edit tab, select Cut to cut the selected item.
9. Close the image without saving it.
10. From the Edit tab, select Paste.
11. In the Analyze menu, choose the tool 3D Objects Counter.
12. Set the threshold. In the example provided in this study, the threshold is set at 2,000.
13. Set the size filter. In this study, it is set between 50 and 500.
14. Be sure that the boxes Objects and Summary are marked.
15. Click on Ok. The number of dots will be described as Objects Detected in the Summary.

Figure 1: Schematic diagram of the LC3 immunofluorescence protocol. Schematic diagram that represents the general protocol provided for LC3 immunofluorescence. Figure created with BioRender.com. Please click here to view a larger version of this figure.

Results

This protocol performs immunofluorescence of LC3 in pancreatic cell lines to determine the autophagy levels in different conditions. The outcome of this experiment was the obtention of cellular images from the red and blue channels, corresponding to LC3 and DAPI. The LC3 images indicate the cellular distribution of this protein, whereas the DAPI shows the nuclear localization. Figure 2A shows a representative image of the immunofluorescence of LC3 and its merge with DAPI staining in PANC-1 c...

Discussion

The method described in this protocol allows for visualizing the endogenous LC3 distribution in the cell and quantifying the autophagic levels under different conditions. Another similar method used to analyze the LC3 distribution and determine autophagy activation involves fluorescence-labeled LC3 transfection (such as RFP-LC3)¹⁹. RFP-LC3 transfection has the advantages of not needing fixation (which allows for applying this method in live cell imaging²⁰), being cheaper, a...

Materials

Name	Company	Catalog Number	Comments
10x Phosphate-Buffered Saline (PBS)	Corning	46-013-CM
12 mm round coverslips	HDA	CBR_OBJ_6467
24 Well- Cell Culture Plate	Sorfa	220300
Absolute ethanol	Biopack	2207.10.00
Alexa Fluor 594 Donkey anti-rabbit IgG (H+L)	Invitrogen	R37119
Confocal Laser Scanning Microscope	Zeiss	LSM 800
DAPI (4',6-diamidino-2-phenylindole, dihydrochloride)	Invitrogen	62248
Dexamethasone	Sigma Aldrich	D4902
DMEN	Sartorius	01-052-1A
Fetal Bovine Serum	NATOCOR	Lintc-634
Gemcitabina	Eli Lilly	VL7502
LC3B (D11) XP Rabbit mAb	Cell Signaling Technology	3868S
Methanol	Anedra	6197
Parafilm "M" (Laboratory Sealing Film)	Bemis/Curwood	PM-996
Pen-Strep Solution	Sartorius	03-031-1B
PP242	Santa Cruz Biotechnology	SC-301606
Trypsin EDTA	Gibco	11570626